Abstract： INTRODUCTION Antiarrhythmic drugs remain a critically important component of the approach to therapy of cardiac arrhythmias.Over the past 20 years,despite their antiarrhythmic efficacy in many pathological settings,Class Ⅰ and Ⅲ antiarrhythmic drugs have been shown to be associated with the development of proarrhythmias and an increase in the likelihood of causing higher mortality by inducing torsade de pointes ventricular tachycardia and other serious adverse reactions.Consequently,the development of safe and effective antiarrhythmic regimens remains a primary focus of contemporary cardiovascular research.